共 204 条
[1]
Cortes JE(2019)Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Leukemia 33 379-389
[2]
Heidel FH(2020)Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy J Hematol Oncol 13 92-3916
[3]
Hellmann A(2019)Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia Blood 134 3916-3545
[4]
Fiedler W(2019)Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial Clin Lymphoma Myeloma Leuk 19 S231-2303
[5]
Smith BD(2019)Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia Blood 134 3916-4649
[6]
Robak T(2019)Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials Future Oncol 15 3531-425
[7]
Montesinos P(2018)Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS Clin Cancer Res 10 2294-71
[8]
Pollyea DA(2003)Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 4642-257
[9]
DesJardins P(2006)Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419-616
[10]
Ottmann O(2016)Application of a hazard-based visual predictive check to evaluate parametric hazard models J Pharmacokinet Pharmacodyn 43 57-20